BioMarin Pharmaceutical, Inc. (BMRN)
65.29
+0.62
(+0.97%)
USD |
NASDAQ |
Aug 31, 16:00
65.29
0.00 (0.00%)
After-Hours: 20:00
BioMarin Pharmaceutical Cash from Operations (TTM) : 857.09M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 857.09M |
| March 31, 2026 | 874.25M |
| December 31, 2025 | 827.99M |
| September 30, 2025 | 913.98M |
| June 30, 2025 | 766.77M |
| March 31, 2025 | 700.26M |
| December 31, 2024 | 572.84M |
| September 30, 2024 | 414.70M |
| June 30, 2024 | 328.86M |
| March 31, 2024 | 280.16M |
| December 31, 2023 | 159.26M |
| September 30, 2023 | 138.56M |
| June 30, 2023 | 161.24M |
| March 31, 2023 | 147.40M |
| December 31, 2022 | 175.90M |
| September 30, 2022 | 180.30M |
| June 30, 2022 | 119.04M |
| March 31, 2022 | 145.59M |
| December 31, 2021 | 304.54M |
| September 30, 2021 | 279.97M |
| June 30, 2021 | 269.12M |
| March 31, 2021 | 214.07M |
| December 31, 2020 | 85.36M |
| September 30, 2020 | 156.09M |
| June 30, 2020 | 140.01M |
| Date | Value |
|---|---|
| March 31, 2020 | 87.94M |
| December 31, 2019 | 48.26M |
| September 30, 2019 | 40.29M |
| June 30, 2019 | 17.37M |
| March 31, 2019 | 7.849M |
| December 31, 2018 | 20.21M |
| September 30, 2018 | -14.55M |
| June 30, 2018 | -23.46M |
| March 31, 2018 | 29.18M |
| December 31, 2017 | -8.757M |
| September 30, 2017 | -23.58M |
| June 30, 2017 | -72.24M |
| March 31, 2017 | -136.83M |
| December 31, 2016 | -227.84M |
| September 30, 2016 | -295.83M |
| June 30, 2016 | -288.31M |
| March 31, 2016 | -255.33M |
| December 31, 2015 | -221.85M |
| September 30, 2015 | -180.43M |
| June 30, 2015 | -186.61M |
| March 31, 2015 | -185.31M |
| December 31, 2014 | -74.21M |
| September 30, 2014 | -58.73M |
| June 30, 2014 | -59.19M |
| March 31, 2014 | -54.48M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Incyte Corp. | 1.980B |
| Vertex Pharmaceuticals, Inc. | 4.293B |
| BridgeBio Pharma, Inc. | -434.37M |
| Ionis Pharmaceuticals, Inc. | -496.43M |